$SRPT

Sarepta Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$71.15 ▲0.028%

Extented Hours

VOLUME

831,638

DAY RANGE

67.47 - 69.91

52 WEEK

61.28 - 101.24

Join Discuss about SRPT with like-minded investors

profile
@AJAJ #droscrew
recently

why what happeend to that now? > @dros said: $SRPT RESUMED

62 Replies 10 👍 6 🔥

profile
@Navneet #droscrew
recently

why the fuck $srpt went down

56 Replies 13 👍 15 🔥

profile
@dros #droscrew
recently

$SRPT RESUMED

110 Replies 14 👍 11 🔥

profile
@dros #droscrew
recently

1000 $SRPT FEB2022 $100 Cs trade 8.1

125 Replies 6 👍 6 🔥

profile
@dros #droscrew
recently

1000 $SRPT FEB2022 $100 Cs trade 8.1

115 Replies 11 👍 6 🔥

profile
@dros #droscrew
recently

Upgrades 11/5: $APO $BIGC $BLDR $CLR $CWEN $EOG $GSK $IGMS $KEP $LITE $LSPD $LUMN $NFLX $NS $QCOM $QLYS $SHAK $SKT $SRPT $SYNA $SYNH $TBPH $VG

145 Replies 8 👍 8 🔥

ST
@StefanAman #StockTraders.NET
recently

I can short just beaten down stocks for now. I got in SRPT for example today for a short

122 Replies 11 👍 14 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Thursday, October 14, 2021 Futures Up/Down % Last Dow 205.00 0.60% 34,461 S&P 500 28.25 0.67% 4,384 Nasdaq 116.50 0.79% 14,880 Stock futures are jumping overnight, extending yesterday’s gains ahead of key earnings reports and inflation data. Stocks advanced on Wednesday as the S&P 500 and Nasdaq outperformed after a choppy session, with Big Tech doing much of the heavy lifting, led by shares of Microsoft, Amazon, Alphabet, and Nvidia. Minutes from the September Federal Reserve policy meeting showed central bankers signaled they could start reducing crisis-era support for the economy in mid-November, although they remained divided about how soon they may need to raise interest rates. Inflation data was in-line with forecast for consumer prices ahead of today’s producer price index at 8:30 AM ET. Banks the other top story with earnings this week, with JPMorgan falling after its third-quarter earnings beat expectations. Bank of America, Citigroup, Wells Fargo and Morgan Stanley are set to report results this morning. In Asian markets, The Nikkei Index rose 410 points to 28,550, while the Shanghai Index was little changed at 3,558. In Europe, the German DAX is rising 130 points to 15,380, while the FTSE 100 gains about 50-points to move just below the 7,200 level. Market sentiment improving after a rough start to the week, helped yesterday on news Port of Los Angeles to go 24/7 joining neighboring Port of Long Beach as the expanded operations would nearly double the hours that cargo can move and help remove the glut at ports and improve inventory for retail and food stores. Oil prices rose by about 1% after the International Energy Agency said that record natural gas prices will boost demand for oil and top oil producer Saudi Arabia dismissed calls for additional OPEC+ supplies. Market Closing Prices Yesterday The S&P 500 Index gained 13.15 points, or 0.30%, to 4,363.80 The Dow Jones Industrial Average little changed, or 0.00%, to 34,377.81 The Nasdaq Composite jumped 105.71 points, or 0.73%, to 14,571.63 The Russell 2000 Index advanced 7.70 points, or 0.34% to 2,241.97 Events Calendar for Today 8:30 AM ET Weekly Jobless Claims…est. 319K 8:30 AM EST Continuing Claims…est. 2.675M 8:30 AM ET Producer Price Index (PPI) Headline MoM for September…est. +0.6% 8:30 AM ET PPI Core: Ex Food & Energy MoM for September…est. +0.5% 8:30 AM ET Producer Price Index (PPI) Headline YoY for September…est. +8.7% 8:30 AM ET PPI Core: Ex Food & Energy YoY for September…est. 7.1% 10:30 AM ET Weekly EIA Natural Gas Inventory Data 11:00 AM ET EIA Weekly Inventory Data Earnings Calendar: Earnings Before the Open: BAC, C, CMC, DPZ, MS, PGR, UNH, USB, WBA, WFC Earnings After the Close: AA, DCT, TACO Other Key Events: Piper Insurance Summit in New York, 10/14 Macro Up/Down Last Nymex 0.87 81.31 Brent 0.97 84.15 Gold 4.90 1,801.60 EUR/USD 0.0014 1.1606 JPY/USD 0.17 113.41 10-Year Note -0.017 1.532% World News China sept. consumer prices rise7% y/y vs. est. 0.8%; China sept. producer prices rise 10.7% y/y vs. est. 10.5% Oil demand is set to jump by half a million barrels per day (bpd) as the power sector and heavy industries switch from other more expensive sources of energy, the IEA said, warning that the energy crunch could stoke inflation and slow the world’s economic recovery from the COVID-19 pandemic. In its monthly report, the IEA increased its global oil demand growth forecast by 170,000 bpd to 5.5 million bpd for 2021 and by 210,000 bpd to 3.3 million bpd for 2022. The agency now expects total oil demand in 2022 to reach 99.6 million bpd Sector News Breakdown Consumer Bed Bath & Beyond ($BBBY) downgraded to Underweight from Equal Weight at Morgan Stanley Wayfair ($W) downgraded to Underweight from Equal Weight at Morgan Stanley Esports Entertainment Group ($GMBL) rises after forecasting higher revenue in FY22 saying it expects net revenue to increase by at least 490% to $100 mln to $105 mln in FY22 driven primarily by the multiple acquisitions completed in calendar 2021 Good Times Restaurants ($GTIM) said Q4 YoY same store sales ended sept. 28, 2021 decreased 0.2% for its good times brand & increased 22.8% for its Bad Daddy’s brand Hyzon Motors ($HYZM) said in 2022, expects to increase capacity to up to 1,000 trucks/year through operational updates, addition of second shift in Europe facility Winnebago ($WGO) announces new $200M share repurchase authorization Energy, Industrials and Materials Occidental ($OXY) agreed to sell its interests in two Ghana offshore fields for $750 million to Kosmos Energy (KOS) paying $550M and Ghana National Petroleum Corporation paying $200M, prior to closing adjustments to reflect an April 1, 2021 effective date The American Petroleum Institute (API) WD-40 ($WDFC) approves new $75M share repurchase plan Matrix Nac ($MTRX) awarded multiple contracts for electrical infrastructure work that, in aggregate, totals about $50 mln The American Petroleum Institute (API) showed a build of 5.21M barrels of oil for the week ending October 8, a draw of 4.58M barrels, distillate inventories show a draw of 2.71M barrels and Cushing inventories show a draw of 2.28M barrels. Steel Dynamics ($STLD) CEO said steel prices, driven to nosebleed highs by surging demand, should start to “erode” by the first part of next year as COVID-related supply bottlenecks ease and new domestic production comes online. UPS ($UPS) upgraded to Buy from Hold at Stifel The Biden administration unveiled plans to hold as many as seven government auctions of offshore wind development rights in the next four years (watch shares of AGR, RDSA) Financials S.-listed Chinese online brokerages Futu Holding ($FUTU) and UP Fintech Holding ($TIGR) face regulatory risks as China’s personal data privacy law takes effect Nov. 1, the official People’s Daily said in an analysis on its website. Such brokerages could violate data privacy rules and also runs compliance risks, the article said. S. Bancorp ($USB) Q3 EPS $1.30 vs. est. $1.16; Q3 revs $5.89B vs. est. $5.77B; return on average assets 1.45% vs. 1.17% y/y; return on average equity 15.9% vs. 12.8% y/y; net charge-offs $147 million, -71% Yoy Healthcare UnitedHealth ($UNH) Q3 adj EPS $4.52 vs. est. $4.41; Q3 revs $72.34B vs. est. $71.19B; Q3 beat helped by a jump in revenue from its Optum unit that manages drug benefits, rising 14%; raises FY21 adjusted EPS view to $18.65-$18.90 from $18.30-$18.80 (est. $18.75) Perrigo ($PRGO) upgraded to Outperform from Market Perform at Raymond James with a $59 price target saying the recently announced acquisition of leading branded consumer play HRA Pharma is expected to immediately boost the company’s profitability back to 2019 levels while delivering on its goal of becoming a pure-play consumer health company by 2023 Sarepta ($SRPT)17M share secondary priced at $81 per share Lucid Diagnostics ($LUCD) 5M share IPO priced at $14 per share Agilent Technologies Inc. ($A) said its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence Turning Point Therapeutics ($TPTX) and EQRx announced a clinical collaboration to evaluate elzovantinib or TPX-0022, Turning Point’s drug candidate targeting MET, SRC, and CSF1R, in combination with aumolertinib, EQRx’s drug candidate targeting EGFR for NSCLC Technology, Media & Telecom Taiwan Semiconductor Manufacturing Co. ($TSM) lifted its revenue growth forecast for 2021, citing an “industry megatrend” of strong chip demand after Q3 rev climbed 22.6% to $14.88B, in line with co’s prior estimated range of $14.6B-$14.9B and vs. est. $14.83B; Q3 profit rose 14% from a year earlier to 156.26 billion New Taiwan dollars (US$5.57 billion) AT&T ($T) upgraded to Sector Weight from Underweight at KeyBanc saying that it appears more difficult to justify further downside from current levels given simplification of the business, reduced leverage, and peers that trade at premiums GitLab ($GTLB)4M share IPO priced at $77.00 Rambus ($RMBS) announced that Rahul Mathur, senior vice president and CFO, will resign from Rambus effective November 15 to pursue another opportunity outside of the semiconductor industry; co affirmed its previously issued guidance for the third quarter fiscal year 2021. E2open ($ETWO) raises FY22 revenue view to $470M-$474M from $369M-$371M (est. $417.13M); adjusted EBITDA is expected to be in the range of $161M-$163M vs. prior guidance of $158M provided at the announcement of the BluJay transaction.

40 Replies 13 👍 6 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Wednesday, October 13, 2021 Futures Up/Down % Last Dow 34.00 0.10% 34,295 S&P 500 5.75 0.14% 4,346 Nasdaq 61.75 0.42% 14,715 U.S. futures recover from overnight losses ahead of Dow component JPMorgan earnings and inflation data later this morning (CPI), reversing overnight losses despite weakness in Dow component Apple (AAPL), which is down about -0.5% after reports it expects to make 10 million fewer iPhone than planned and is poised to slash iPhone production goal due to chip crunch. Oil prices and Treasury yields decline, while gold rises ahead of a key reading of consumer price September inflation. Futures are getting a boost after better economic data in China as September exports rose 28.1% from last year as consumer demand outpace supply chain disruptions and power shortages, while last night’s passage of a debt ceiling extension by House lawmakers puts at least one market concern to the side until early December. In Asian markets, The Nikkei Index fell -90 points to 28,140, the Shanghai Index rose 14 points to 3,561 and the Hang Seng Index was closed. In Europe, the German DAX is up over 100 points to 15,250, while the FTSE 100 is slightly lower at 7,120. U.S. stocks ended lower following a choppy session on Tuesday, with investors nervous about upcoming third-quarter earnings reports. In addition to the CPI data, the Federal Reserve will release minutes from its last policy meeting, and investors are looking for further clues on when the central bank could begin tapering its bond-buying program. Market Closing Prices Yesterday The S&P 500 Index dropped -10.54 points, or 0.24%, to 4,350.65 The Dow Jones Industrial Average fell -117.72 points, or 0.34%, to 34,378.34 The Nasdaq Composite slipped -20.28 points, or 0.14%, to 14,465.92 The Russell 2000 Index advanced 13.63 points, or 0.61% to 2,234.27 Events Calendar for Today 7:00 AM ET MBA Mortgage Applications Data 8:30 AM ET Consumer Price Index (CPI) Headline MoM for September…est. +0.3% 8:30 AM ET CPI Core: Ex Food & Energy MoM for September…est. +0.2% 8:30 AM ET Consumer Price Index (CPI) Headline YoY for September…est. +5.3% 8:30 AM ET CPI Core: Ex Food & Energy YoY for September…est.+4.0% 10:30 AM ET Weekly DOE Inventory Data 4:30 PM ET API Weekly Inventory Data Earnings Calendar: Earnings Before the Open: AYR, BLK, DAL, JPM, SOTK Earnings After the Close: ETWO, ODC Other Key Events: China CPI, PPO for September Macro Up/Down Last Nymex -0.56 80.08 Brent -0.60 82.82 Gold 11.60 1,772.80 EUR/USD 0.0034 1.1562 JPY/USD -0.04 113.56 10-Year Note -0.015 1.565% World News China September exports rose1% from last year as consumer demand outpace supply chain disruptions and power shortages Japanese Core Machine Orders (M/M) Aug: -2.4% (exp 1.4%; previous 0.9%); Core Machine Orders (Y/Y) Aug: 17.0% (exp 13.9%; previous 11.1%) The House on Tuesday voted along party lines to raise the U.S. borrowing limit into December, as Democratic lawmakers wrestled with how to set a new ceiling for U.S. debt later this year over Republican resistance. Sector News Breakdown Consumer Duckhorn Portfolio Inc ($NAPA) said selling stockholders are offering 12 mln shares of common stock Monster Beverage ($MNST) downgraded to Hold from Buy at Jefferies Energy, Industrials and Materials International Paper ($IP) announces up to $2B share repurchase program Boeing ($BA) is the latest federal contractor to mandate COVID-19 vaccinations for all employees by December 8 under the Biden administration’s new rules saying its 125K U.S. employees must show proof of vaccination or have an approved religious or medical exemption by the deadline. Yesterday, Chicago soybean futures fell to the lowest level in nearly a year following a U.S. Department of Agriculture report that showed larger than expected yields of soybeans and corn; the USDA showed an uptick of nearly 100M bushels to U.S. corn ending stocks Glencore Plc ($GLNCY) said that it had reached an agreement to sell its zinc business in Bolivia to Canada’s Santa Cruz Silver Mining for some $110M Rattler Midstream LP ($RTLR), a subsidiary of Diamondback Energy, Inc. (FANG) announces strategic midland basin gas gathering & processing joint venture; invested approximately $104 mln in cash to acquire a minority interest in joint venture Vistra ($VST) announces $2 billion share repurchase program Gran Tierra Energy Inc. ($GTE) said that Q3 production grew 53% and that it expects the gains to continue in Q4; said it has produced an average of 28,957 barrels of oil a day in the quarter, compared with 18,944 barrels a day in the prior year period and 23,035 barrels a day QoQ Greenbrier ($GBX) announced the acquisition of more than 3,600 railcars, a portion of which will be held in GBX Leasing Financials BlackRock ($BLK) Q3 adj EPS $10.95 vs. est. $9.35; Q3 revs $5.05B vs. est. $4.9B; qtrly long-term net inflows of $98 billion; assets under management at qtr-end were $9.46 trillion vs $7.81 trillion at end of Q3 AvidXchange ($AVDX)64M share IPO price $25.00 AllianceBernstein L.P. ($AB) preliminary assets under management decreased to $742 billion during September 2021 from $761B at the end of August. Firmwide net inflows were outweighed by market depreciation, resulting in a 2% decline in AUM. In the month of September, net inflows to Retail and Private Wealth were partially offset by net outflows from Institutions. Ellington Financial Inc ($EFC) commenced an underwritten public offering of 5 mln shares of common stock RenaissanceRe Holdings Ltd. ($RNR) estimates that losses from certain 2021 catastrophe events will have a net negative impact of approximately $725 million on the Company’s Q3 results of operations Manning & Napier ($MN) preliminary assets under management (AUM) of $22B for September, compared with $22.7B as of Aug.31. Healthcare Sarepta ($SRPT) announces $500M common stock offering and guiding Q3 revs about $166.9M vs. est. $172M; had approximately $1.6 bln in cash, cash equivalents and investments as of September 30, 2021 CRISPR Therapeutics ($CRSP) shares slipped after announcing updated results from the company’s early-stage trial of its CAR-T cell therapy CTX110 as two patients in the phase 1 trial experienced Grade 3 or higher infections, with one patient having HHV-6 encephalitis, and another developing pseudomonal sepsis that resolved in four days. CytoSorbents ($CTSO) receives full FDA investigational device exemption approval to begin U.S. star-d trial on apixaban and rivaroxaban removal by the DrugSorb-ATR™ antithrombotic removal system during urgent cardiothoracic surgery Homology Medicines ($FIXX) announced the pheEDIT Phase 1 clinical trial for HMI-103, a one-time, in vivo product candidate that utilizes a gene editing approach for phenylketonuria, or PKU, based on the investigational new drug application, or IND, clearance from the FDA Apollo EndoSurgery ($APEN)4M share Spot Secondary priced at $7.75 Bicycle Therapeutics ($BCYC)24M share Secondary priced at $54.00 Relay Therapeutics ($RLAY)21M share Secondary priced at $26.50 Biogen ($BIIB) announces results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Teva Pharmaceuticals Europe BV, a European affiliate of Teva ($TEVA) presents new analyses of the COBRA study, which concluded no evidence was found to suggest that infants were adversely affected by maternal exposure to glatiramer acetate (GA) during pregnancy and breastfeeding with use of COPAXONE Technology, Media & Telecom Apple ($AAPL) suppliers Broadcom ($AVGO), Texas Instruments ($TXN) struggling to deliver enough chips; Apple expects to make 10 million fewer iPhone than planned and is poised to slash iPhone production goal due to chip crunch – Bloomberg (watch shares of $AAPL suppliers including $CRUS, $QRVO, $STM, $AVGO, $SWKS) SAP AG ($SAP) raised its 2021 projections for non-IFRS cloud revenue at constant currencies to range from EUR9.4B to EUR9.6B, up from its earlier view of EUR9.3 billion and EUR9.5 billion; also boosts cloud and software revenue at constant currencies view to EUR23.8 billion to EUR24.2 billion from its earlier view of EUR23.6 billion to EUR24 billion. Qualcomm ($QCOM) announces new $10.0 billion stock repurchase authorization IAC Inc. ($IAC) reports September Angi Inc. total revenue up 18% from last year with Dotdash revenue up 25%, and its Search business revenue up 74% from last year and Emerging & Other revenue was up 33% from last year Vimeo Inc ($VMEO) total revenue for September 2021 up 33%; subscribers for September 2021 up 14%; ARPU for September 2021 up 16% Smart Global Holding ($SGH) Q4 adj EPS $2.16 vs. est. $1.60; Q4 revs $467.7M vs. est. $461.3M; sees Q1 adj EPS $1.80-$2.20 vs. est. $1.49; sees Q1 revenue $440M-$480M vs. est. $458.55M; GAAP gross margin of 25.2%, up 620 basis points versus the year ago quarter and non-GAAP gross margin of 26.4%, up 690 basis points versus the year ago quarter VOXX International ($VOXX) 2Q EPS $0.01 vs est. $0.07 on sales $143.1Mm vs est. $134.4Mm

70 Replies 9 👍 11 🔥

profile
@dros #droscrew
recently

maybe, not yet > @Navneet said: dros are you taking $srpt ?

150 Replies 11 👍 15 🔥

profile
@Navneet #droscrew
recently

he can easily make wide spreads for $srpt

104 Replies 11 👍 9 🔥

profile
@Navneet #droscrew
recently

dros are you taking $srpt ?

80 Replies 13 👍 14 🔥

profile
@Navneet #droscrew
recently

finally dros posted $srpt

140 Replies 12 👍 12 🔥

profile
@dros #droscrew
recently

5000 $SRPT JAN2022 $100 Cs trade 12

72 Replies 15 👍 8 🔥

profile
@Navneet #droscrew
recently

some news gonna drop on $srpt ! it was 180$ stock

64 Replies 12 👍 10 🔥

profile
@Navneet #droscrew
recently

$srpt 100 calls jan 2022 12.00 //8 million

78 Replies 9 👍 12 🔥

profile
@Baljit123 #StockTraders.NET
recently

BBIG - Clear hot chick of the day with 20M volume. This is REG SHO meaning the borrow is tough across most brokers. IMO this is an AVOID on the short side until the first red day GANX - Ideally a bounce toward 10.20 / 10.40 / 10.60 to scale in short RNXT - Looking for a r/g REJECTION at the open for a nail and bail. If not, 10.50 rejection SRPT - This is NON NICHE so I will avoid this long and short **We only use size when there is an EDGE. If there is NO EDGE there is NO TRADE. Because it is a slower day I am sizing down, reducing size and accepting a small day. My goal is to preserve mental capital .. not waste it gambling on random setups I will stick to the process and walk at zombie times as usual

107 Replies 14 👍 7 🔥

profile
@bunnytoad69 #droscrew
recently

sorry to hear that @pdttrader about your SRPT

76 Replies 7 👍 10 🔥

profile
@AJAJ #droscrew
recently

kada marri .. nuvvu na question ki jawabu ivvu babu first > @pdttrader said: champesaru SRPT ni

104 Replies 8 👍 8 🔥

PD
@pdttrader #droscrew
recently

champesaru SRPT ni

45 Replies 14 👍 11 🔥

profile
@Snowcow #droscrew
recently

looking back at $srpt buying the shares and selling the 18c seemed like a good play

114 Replies 9 👍 10 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Moderna ($MRNA) Q2 EPS $6.46 vs. est. $6.04; Q2 revs $4.4B vs. est. $4.28B; expects dose capacity for its covid-19 vaccine in fy 2021 to be between 800 mln and 1 bln doses; advance purchase agreements signed for expected product sales of $20 bln in 2021, including sales already recorded in 6 months ended June 30; signed agreements for $12 bln worth of sales for covid-19 vaccine in 2022, option for about $8 bln more; continue to expect $450 mln -$550 mln of capital investments for 2021 Cigna ($CI) Q2 adj EPS $5.24 vs. est. $4.96; Q2 revs $43.13B vs. est. $41.31B; pharmacy customer base at Q2 grew to 101.9M, an organic increase of 3.1M year to date; total medical customer base at Q2 was 17M, an increase of 279,000 customers YTD; Q2 profit overall fell -16% hurt by higher medical costs; backs year EPS but ups its rev guidance to at least $170B from $166B Nevro ($NVRO) slides after withdrawing FY forecast on COVID-19 concerns and guided Q3 sales between $90M-$93M which is below analyst estimates of $114.7M Regeneron Pharma ($REGN) phase 3 Trial of Libtayo combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Abiomed ($ABMD) Q1 adj EPS $1.10 vs. est. $1.05; Q1 revs $252.6M vs. est. $240.91M; raises FY22 revenue view to $1.03B-$1.05B from prior $990M-$1.03B (22%-24% growth); expects its fiscal year 2022 non-GAAP operating margin to be in the range of 24% to 26% Amedisys ($AMED) announces new $100M share repurchase program; Q2 adj EPS $1.69 vs. est. $1.67; Q2 revs $564.2M vs. est. $566.19M; guides 2021 adj EPS $6.37-$6.49 vs. est. $6.96; sees 2021 adj net service revenue $2.23B-$2.245B. Evolent Health ($EVH) 2Q EPS ($0.11) vs est. ($0.04) on revs $222.1Mm vs est. $216.9Mm; guides 3Q revs $215-230Mm vs est. $217.7Mm, sees FY revs $870-900Mm vs est. $870.8Mm; announces agreement to acquire Vital Decisions outstanding equity interests for aggregate price up to $130Mm, says transaction is accretive to EBITDA/share before synergies McKesson ($MCK) Q1 adj EPS $5.56 vs. est. $4.15; Q1 revs $62.7B vs. est. $59.99B; raises FY22 adj EPS view to $19.80-$20.40 from prior view $18.85-$19.45 (est. $19.23) 1life Healthcare, Inc. ($ONEM) Q2 EPS loss (-$0.30) vs. est. loss (-$0.20); Q2 revs $120.4M vs. est. $115.7M; sees Q3 revs $113M-$120M vs. est. $118M; sees year revs $475M-$485M vs. est. $482.3M; Membership count as of quarter-end was 621,000 compared to 475,000, a 31% increase; Adjusted EBITDA was positive $6.9 million, or 6% of net revenue Sarepta Therapeutics ($SRPT) Q2 non-GAAP EPS loss (-$1.52) vs. est. loss (-$1.26); net product sales for q2 reached $141.8 mln, a 27% increase over same quarter of prior year; raises full-year product revenue guidance by nearly $30 mln to between $565 mln to $575 mln Tandem Diabetes ($TNDM) 2Q revs $172.1Mm vs est. $143.4Mm; guides FY sales $670-685Mm vs est. $637Mm; guides FY adj EBITDA mgn about 15% vs est. 13.5% Industrials & Materials Albemarle ($ALB) Q2 adj EPS $0.89 vs. est. $0.83; Q2 revs $773.9M vs. est. $788.6M; qtrly lithium net sales of $320.3 mln increased $36.6 mln yoy primarily driven by higher volumes; full-year 2021 net sales guidance improved vs previous guidance primarily due to increased lithium sales, improving catalysts trends – sees year sales $3.3B-$3.4B vs. est. $3.24B Hillenbrand ($HI) 3Q adj EPS $0.85 vs est. $0.76 on revs $695Mm; guides 4Q adj EPS $0.82-0.92 vs est. $0.85, sees 4Q revs $713-738Mm vs est. $709.1Mm Maxar Technologies ($MAXR) 2Q EPS $0.60 vs est. $0.14 on revs $473Mm vs est. $441.5Mm Summit Materials ($SUM) 2Q EPS $0.48 vs est. $0.52 on revs $618.5Mm vs est. $647.1Mm; no change to FY guide Valvoline ($VVV) Q3 adj EPS $0.55 vs. est. $0.45; Q3 revs $792M vs. est. $745.32M; Q3 retail Services system-wide same-store sales grew 40.5%; Q3 same-store sales rose 27%; sees FY sales growth 25%-26% and FCF $250M-$270M Media & Telecom Fox Corp. ($FOXA) Q4 adj EPS $0.65 vs. est. $0.57; Q4 revs $2.89B vs. est. $2.75B; raises semi-annual dividend to 24c; cable network programming reported quarterly segment revenues of $1.40B, an increase of $128M; affiliate revenues increased 10% with 16% growth at the television segment and 6% growth at the cable network programming segment in q4 Roku Inc. ($ROKU) Q2 EPS 52c vs est. 13c on revs $645M vs est. $618.4M, average rev per user $36.46 (+46% YoY), active accounts 55.1M vs est. 55.8M; at midpoint of Q3 guidance, sees revs $675M-$685M vs est. $645M, gross profit $315M-$325M, adj EBITDA $60M-$70M, net income (-$3M)-$7M, anticipates sequential increases in operating expenses in 2H from investments in headcount, product development, and sales & marketing Technology Amdocs Ltd. ($DOX) 3Q adj EPS $1.35 vs est. $1.18 on revs $1.066B vs est. $1.06B; guides 4Q adj EPS $1.13-1.19 vs est. $1.28, sees 4Q revs $1.065-1.105B vs est. $1.087B Booking Holdings ($BKNG) 2Q adj EPS ($2.55) vs est. ($2.04) on revs $2.2B vs est. $1.9B, encouraged by sequential improvement in booking trends with 2Q room nights +59% vs 1Q; said in in q2, we saw the first sequential increase in the number of properties on booking.com and lowest number of properties coming off of our platform since the onset of the covid-19 pandemic DXC Technology ($DXC) Q1 adj EPS $0.84 vs. est. $0.74; Q1 revs $4.14B vs. est. $4.11B; Q2 guidance falls short of views but backs year EPS view $3.45-$3.65 vs. est. $3.56 and backs FY22 revenue view $16.6B-$16.8B (est. $16.74B); Bookings of $4.6 billion and book-to-bill ratio of 1.12x in Q1 FY22 Electronic Arts ($EA) Q1 EPS $0.71 vs. est. $0.62; Q1 net bookings $1.336B vs. est. $1.28B; sees Q2 EPS roughly $0.36 vs. est. $1.07; sees Q2 net bookings $1.725B vs. est. $1.62B; raises FY22 EPS view to $1.58 from $1.34 and ups FY21 bookings view to $7.4B from $7.3B Fastly Inc. ($FSLY) shares fall -18%; Q2 adj EPS ($$0.15) vs est. ($0.17) on revs $85.03M vs est. $85.7M, sees Q3 EPS loss (21c)-(18c) vs est. (18c) on revs $82M-$85M vs est. $97.9M, and forecasts FY EPS (65c)-(57c) vs est. (43c) on revs $340M-$350M vs est. $382.5M GoDaddy ($GDDY) Q2 EPS $0.27 vs. est. $0.32; Q2 revs $931.3M vs. est. $919.7M; total bookings of $1.055B, up 12.7% year over year, or 10.6% on a constant currency basis; Domains revenue of $436.7 million, up 18.2% yoy; Hosting and presence revenue of $318.5 million, up 9.0% yoy; Business applications revenue of $176.1 million, up 21.8% yoy; sees year revs $3.75B, in-line HubSpot ($HUBS) 2Q adj EPS $0.43 vs est. $0.32 on revs $310.8Mm vs est. $296Mm; guides 3Q adj EPS $0.42-0.44 vs est. $0.39, sees 3Q revs $325-327Mm vs est. $318.7Mm; guides FY revs $1.268-1.272B vs est. $1.244B MercadoLibre ($MELI) Q2 EPS $1.37 vs est. $0.19 on revs $1.7B vs est. $1.48B with commerce revs +96.4% YoY and fintech revs +88.9%; unique active users 75.9M in quarter (+47.4% YoY), total payment volume through Mercado Pago topped $17.5B (+56.3% in USD), gross merchandise volume $7B (+39.2% in USD) Ping Identity ($PING) 2Q adj EPS $0.11 vs est. $0.04 on revs $78.9Mm vs est. $66.1Mm; guides 3Q revs $65-70Mm vs est. $65.1Mm, sees 3Q total ARR $286-288Mm; guides FY revs $278-285Mm vs est. $269.3Mm, sees FY total ARR $304-306Mm Qorvo ($QRVO) Q1 EPS $2.83 vs. est. $2.45; Q1 revs $1.11B vs. est. $1.08B; sees Q2 EPS $3.24 at midpoint vs. est. $3.02; sees Q2 revenue $1.24B-$1.26B vs. est. $1.21B Trimble Inc. ($TRMB) Q2 adj EPS $0.72 vs. est. $0.59; Q2 revs $945.3M vs. est. $867.8M; sees FY21 adj EPS $2.45-$2.65 vs. est. $2.45; sees FY21 adjusted revenue $3.55B-$3.65B vs. est. $3.48B; Q2 annualized recurring revenue (ARR) was $1.35 billion, up 11% yoy Western Digital ($WDC) 4Q adj EPS $2.16 vs est. $1.51 on revs $4.9B vs est. $4.55B; guides 1Q revs $4.9-5.1B vs est. $4.9B, sees 1Q adj EPS $2.25-2.55 vs est. $2.05

123 Replies 7 👍 12 🔥

profile
@RedSunCap #droscrew
recently

SRPT nice swing

129 Replies 8 👍 15 🔥

profile
@Navneet #droscrew
recently

$srpt still going up

59 Replies 6 👍 11 🔥

profile
@Navneet #droscrew
recently

sold $srpt 12.00 from 1.85

110 Replies 9 👍 14 🔥

profile
@Navneet #droscrew
recently

well i have weekly expiry for $srpt

72 Replies 9 👍 11 🔥

profile
@dros #droscrew
recently

resistance around $85 > @Navneet said: dros whats next levels for $srpt

44 Replies 12 👍 10 🔥

profile
@Navneet #droscrew
recently

dros whats next levels for $srpt

122 Replies 12 👍 9 🔥

profile
@Navneet #droscrew
recently

$srpt 350% up

114 Replies 9 👍 8 🔥

profile
@Navneet #droscrew
recently

$srpt also flying

75 Replies 11 👍 9 🔥

profile
@Navneet #droscrew
recently

$srpt i would play sympathy play for $biib

59 Replies 9 👍 12 🔥

profile
@thegiz18 #ivtrades
recently

$SRPT nice pop on drug trial

131 Replies 9 👍 14 🔥

profile
@thegiz18 #ivtrades
recently

Tonights earnings include $ETSY, $FSLY, $FLT, $FMC, $GDOT, $MET, $PYPL, $RKT, $SBRA, $SRPT, $TNDM, $SKT, $UBER

69 Replies 12 👍 15 🔥

profile
@optionsGOAT #droscrew
recently

nav i have the may 21 SRPT

59 Replies 11 👍 6 🔥

profile
@Navneet #droscrew
recently

i distributed in $srpt $fubo $jmia

117 Replies 13 👍 13 🔥

profile
@Navneet #droscrew
recently

u remember dros i have $srpt equity

66 Replies 9 👍 6 🔥

profile
@Navneet #droscrew
recently

$srpt gonna save my profile

110 Replies 7 👍 15 🔥

profile
@Navneet #droscrew
recently

i hope $srpt runs

58 Replies 12 👍 7 🔥

profile
@dros #droscrew
recently

nah > @Navneet said: dros do you see any flow in $srpt ?

51 Replies 11 👍 6 🔥

profile
@Navneet #droscrew
recently

dros do you see any flow in $srpt ?

75 Replies 13 👍 11 🔥

profile
@dros #droscrew
recently

SRPT chart looks like it needs a real miracle

131 Replies 12 👍 12 🔥

profile
@optionsGOAT #droscrew
recently

nav if SRPT goes the one we got the spread.. party on me ;)

143 Replies 9 👍 15 🔥

profile
@Navneet #droscrew
recently

@optionsGOAT $srpt news will come soon ! and it will pop like crazy

143 Replies 7 👍 10 🔥

profile
@Navneet #droscrew
recently

took SRPT 130/175 june spreads 0.35

96 Replies 10 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

$SRPT is toast

141 Replies 13 👍 15 🔥

profile
@thegiz18 #ivtrades
recently

Earnings after close today include $DDD, $CLOV, $INO, $LMND, $NIO, $OMER, $NVAX, SRPT, $ZM

147 Replies 11 👍 7 🔥

profile
@Benlax #droscrew
recently

Some implied moves for #earnings next week - 470 companies reporting(1of3):$MELI 8.7% $LMND 15.9% $DDD 16.8% $SILK 13.2% $SWCH 9.9% $SRPT 7.9% $IPI 20.3% $ANF 12.5% $AZO 5.6% $CHS 35.3% $IGT 14.9% $LL 14.6% $VEEV 9.8% $AMBA 12.7% $DLTR 7.3% $WEN 7.9% $DY 15.3% $MRVL 7.9% $SE 11.6% $FUBO 11.9% $SNOW 11.6% $AVGO 5.6% $COST 3.8% $NIO 15.9% $ZM 12.9% $OKTA 8.0% $SPLK 10.1% $TGT 6.7% $AEO 8.9% $KSS 10.6% $BOX 12.4% $JWN 13.3% $WKHS 19.5% $SSYS 14.6% $CDLX 20.5% $YEXT 14.7% $BJ 11.3% $KR 5.6% $CIEN 9.6% $MIK 22.5% $BURL 7.2% $BZUN 17.0% $PRPL 18.3% $SDC 15.7% $SWBI 19.3% $HEAR 20.7% $BIG 16.4% $HIBB 15.9% $RUTH 15.1% $GSX 15.6% $NVAX 13.6%

70 Replies 9 👍 7 🔥

profile
@Navneet #droscrew
recently

$srpt and $fubo

128 Replies 13 👍 11 🔥

profile
@Navneet #droscrew
recently

$lmnd 80.00 recovered it and kept all those money in fubo and srpt stocks

89 Replies 6 👍 12 🔥

profile
@Navneet #droscrew
recently

lol i got $fubo and $srpt stocks

130 Replies 6 👍 10 🔥

Key Metrics

Market Cap

6.06 B

Beta

0.99

Avg. Volume

822.35 K

Shares Outstanding

87.50 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-03

Next Dividend Date

Company Information

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.

CEO: Douglas Ingram

Website:

HQ: 215 1st St Ste 415 Cambridge, 02142-1213 Massachusetts

Related News